

Claire Corcoran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10802038/publications.pdf>

Version: 2024-02-01

20
papers

2,393
citations

516710

16
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

4455
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	7.0	41
2	Concordance of <i>BRCA1</i> , <i>BRCA2</i> (BRCA), and <i>ATM</i> mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 26-26.	1.6	24
3	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
4	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
5	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2050-2059.	7.0	96
6	Accurate detection of low prevalence <i>AKT1</i> E17K mutation in tissue or plasma from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0175779.	2.5	10
7	Optimised Pre-Analytical Methods Improve <i>KRAS</i> Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). <i>PLoS ONE</i> , 2016, 11, e0150197.	2.5	133
8	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. <i>Oncotarget</i> , 2015, 6, 32774-32789.	1.8	203
9	Receptor Tyrosine Kinases and Drug Resistance: Development and Characterization of In Vitro Models of Resistance to RTK Inhibitors. <i>Methods in Molecular Biology</i> , 2015, 1233, 169-180.	0.9	9
10	Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2014, 74, 3821-3833.	0.9	34
11	miR-630 targets <i>IGF1R</i> to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. <i>Molecular Cancer</i> , 2014, 13, 71.	19.2	66
12	miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. <i>Prostate</i> , 2014, 74, 1320-1334.	2.3	188
13	Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. <i>European Journal of Cancer</i> , 2013, 49, 1845-1859.	2.8	192
14	The potential of miR-630, an <i>IGF1R</i> regulator, as a predictive biomarker for HER2-targeted drugs.. <i>Journal of Clinical Oncology</i> , 2013, 31, 620-620.	1.6	0
15	Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes. <i>PLoS ONE</i> , 2012, 7, e50999.	2.5	367
16	The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. <i>Proteomics</i> , 2012, 12, 2115-2126.	2.2	13
17	Intracellular and Extracellular MicroRNAs in Breast Cancer. <i>Clinical Chemistry</i> , 2011, 57, 18-32.	3.2	197
18	Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling. <i>Methods in Molecular Biology</i> , 2011, 784, 181-195.	0.9	89

#	ARTICLE	IF	CITATIONS
19	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	19.2	170
20	Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 613-625.	2.5	67